Close Bookmark and Share This Page

Save to Browser Favorites / Bookmarks

Ask backflip blinklist BlogBookmark Bloglines BlogMarks Blogsvine BuddyMarks BUMPzee! CiteULike Connotea del.icio.us

Digg diigo DotNetKicks DropJack dzone Facebook Fark Faves Friendsite folkd.com Furl Google

Jamespot Jeqq Kaboodle kirtsy linkaGoGo LinkedIn Ma.gnolia Mister Wong Mixx MySpace Netvouz Newsvine

oneview OnlyWire PlugIM Propeller Reddit Segnalo Shoutwire Simpy Slashdot Surphace Sphinn Spurl

Squidoo StumbleUpon Technorati ThisNext Twitter Webride Windows Live Yahoo!

Email This to a Friend

  Link HTML: 

 Permalink: 

 If you like this then please subscribe to the RSS Feed.

Powered by Bookmarkify™

More »

Possible take over canidates  and really do your dd. I cannot offer investment advice. I can only offer Tips. My work day never stops  for the benefit of members.

NeurogesX Inc (NASDAQ: NGSX) – somewhat mature biotech in the pain management industry. Its lead product, Qutenza, eases neuropathic pain. It already has two market approved products and another sitting in Phase 3 of clinical trials.
Repligen Corp (NASDAQ: RGEN) – develops novel therapeutic products for neurological disorders. Like NeurogesX, Repligen has receives income from products already on the market. The buyout potential comes from its pipeline, which has one product in Phase 3, and another in Phase 2 clinical trials.

regards

Don

Regards,

Don